Nebivolol
- Generic Name
- Nebivolol
- Brand Names
- Bystolic
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25F2NO4
- CAS Number
- 118457-14-0
- Unique Ingredient Identifier
- 030Y90569U
- Background
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta blockers are generally not first l...
- Indication
Nebivolol is indicated to treat hypertension.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 2760
- Registration Number
- NCT03778554
- Locations
- 🇩🇰
Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23, Copenhagen, Denmark
Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke
- Conditions
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 60
- Registration Number
- NCT03655964
- Locations
- 🇬🇷
AHEPA University Hospital, Thessaloniki, Greece
Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 41
- Registration Number
- NCT02710071
Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Dong-A University
- Target Recruit Count
- 62
- Registration Number
- NCT02619526
- Locations
- 🇰🇷
Department of Internal Medicine,Dong-A University College of Medicine, Busan, Korea, Republic of
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 165
- Registration Number
- NCT02467400
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Comparative Study of the Effects of Telmisartan and Nebivolol
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 80
- Registration Number
- NCT02057328
- Locations
- 🇬🇷
Hypertension-ABPM Center 3rd department of Internal Medicine, Thessaloniki, Greece
Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 11
- Registration Number
- NCT02053246
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Non-invasive Haemodynamic Assessment in Hypertension
- Conditions
- Interventions
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2018-03-13
- Target Recruit Count
- 144
- Registration Number
- NCT01996085
- Locations
- 🇵🇱
Military Institute of Medicine, Warsaw, Mazovia, Poland
Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
- Conditions
- Interventions
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 70
- Registration Number
- NCT01961323
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Safety Study of Nebivolol for COPD Patients
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- University of Chicago
- Registration Number
- NCT01939990
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.